Target Price | $100.80 |
Price | $86.54 |
Potential |
16.48%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target Intra-Cellular Therapies, Inc. 2025 .
The average Intra-Cellular Therapies, Inc. target price is $100.80.
This is
16.48%
register free of charge
$135.00
56.00%
register free of charge
$79.00
8.71%
register free of charge
|
|
A rating was issued by 16 analysts: 14 Analysts recommend Intra-Cellular Therapies, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Intra-Cellular Therapies, Inc. stock has an average upside potential 2025 of
16.48%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 464.37 | 672.68 |
85.52% | 44.86% | |
EBITDA Margin | -34.21% | -16.12% |
67.44% | 52.88% | |
Net Margin | -33.21% | -9.38% |
71.07% | 71.75% |
15 Analysts have issued a sales forecast Intra-Cellular Therapies, Inc. 2024 . The average Intra-Cellular Therapies, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Intra-Cellular Therapies, Inc. EBITDA forecast 2024. The average Intra-Cellular Therapies, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Intra-Cellular Therapies, Inc. Analysts have issued a net profit forecast 2024. The average Intra-Cellular Therapies, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.46 | -0.60 |
46.32% | 58.90% | |
P/E | negative | |
EV/Sales | 12.14 |
12 Analysts have issued a Intra-Cellular Therapies, Inc. forecast for earnings per share. The average Intra-Cellular Therapies, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Intra-Cellular Therapies, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Intra-Cellular Therapies, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.